These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11391159)

  • 1. Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters.
    Nelson PW; Mittler JE; Perelson AS
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):405-12. PubMed ID: 11391159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    Benson CA; Deeks SG; Brun SC; Gulick RM; Eron JJ; Kessler HA; Murphy RL; Hicks C; King M; Wheeler D; Feinberg J; Stryker R; Sax PE; Riddler S; Thompson M; Real K; Hsu A; Kempf D; Japour AJ; Sun E
    J Infect Dis; 2002 Mar; 185(5):599-607. PubMed ID: 11865416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
    Notermans DW; Jurriaans S; de Wolf F; Foudraine NA; de Jong JJ; Cavert W; Schuwirth CM; Kauffmann RH; Meenhorst PL; McDade H; Goodwin C; Leonard JM; Goudsmit J; Danner SA
    AIDS; 1998 Jan; 12(2):167-73. PubMed ID: 9468365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
    Perelson AS; Neumann AU; Markowitz M; Leonard JM; Ho DD
    Science; 1996 Mar; 271(5255):1582-6. PubMed ID: 8599114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
    Lucas GM; Chaisson RE; Moore RD
    AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral replication under combination antiretroviral therapy: a comparison of four different regimens.
    Ghani AC; Ferguson NM; Fraser C; Donnelly CA; Danner S; Reiss P; Lange J; Goudsmit J; Anderson RM; De Wolf F
    J Acquir Immune Defic Syndr; 2002 Jun; 30(2):167-76. PubMed ID: 12045679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.
    Ioannidis JP; Havlir DV; Tebas P; Hirsch MS; Collier AC; Richman DD
    AIDS; 2000 Jul; 14(11):1481-8. PubMed ID: 10983634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay.
    Herz AV; Bonhoeffer S; Anderson RM; May RM; Nowak MA
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7247-51. PubMed ID: 8692977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice.
    Romano L; Peduzzi C; Venturi G; Di Pietro M; Carli T; Corsi P; Gonnelli A; Valensin PE; Zazzi M
    J Acquir Immune Defic Syndr; 2002 Aug; 30(5):533-5. PubMed ID: 12154345
    [No Abstract]   [Full Text] [Related]  

  • 13. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
    JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
    HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
    Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C
    AIDS; 2010 Jan; 24(2):223-30. PubMed ID: 20010070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy.
    Eastman PS; Mittler J; Kelso R; Gee C; Boyer E; Kolberg J; Urdea M; Leonard JM; Norbeck DW; Mo H; Markowitz M
    J Virol; 1998 Jun; 72(6):5154-64. PubMed ID: 9573287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice.
    Romano L; Venturi G; Giomi S; Pippi L; Valensin PE; Zazzi M
    J Med Virol; 2002 Feb; 66(2):143-50. PubMed ID: 11782921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.